|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 1. Patient Demographic Data for 10 Phase II and Phase III Short-term MDD Trials\*** | | | | | | |
| Characteristic | Placebo  (n=1621) | Vortioxetine (n=2616) | | | | Duloxetine (n=753) |
|  |  | 5 mg  (n=1013) | 10 mg  (n=699) | 15 mg  (n=449) | 20 mg  (n=455) |  |
| Sex, n (%)  Male  Female | 574 (35.4)  1047 (64.6) | 354 (34.9)  659 (65.1) | 219 (31.3)  480 (68.7) | 141 (31.4)  308 (68.6) | 143 (31.4)  312 (68.6) | 239 (31.7)  514 (68.3) |
| Race, n (%)  Asian  Caucasian  Black/African American  Othera | 63 (3.9)  1327 (81.9)  225 (13.9)  6 (0.4) | 69 (6.8)  804 (79.4)  133 (13.1)  7 (0.7) | 66 (9.4)  536 (76.7)  88 (12.6)  9 (1.3) | 6 (1.3)  372 (82.9)  69 (15.4)  2 (0.4) | 5 (1.1)  358 (78.7)  87 (19.1)  5 (1.1) | 39 (5.2)  637 (84.6)  75 (10.0)  2 (0.3) |
| Age, years  Mean  Minimum, maximum | 46.2  18, 85 | 48.0  18, 88 | 44.6  18, 75 | 44.7  18, 75 | 44.0  18,75 | 49.6  18, 87 |

MDD, major depressive disorder.

\*For studies included see Table 1.

a Includes American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Other, and Unknown categories.

|  |  |
| --- | --- |
| **Supplementary Table 2. Patient Demographic Data for 3 Long-term MDD Trials\*** | |
| **Characteristic** | Total (N=1956) |
| Sex, n (%)  Male  Female | 605 (30.9)  1351 (69.1) |
| Race, n (%)  American Indian or Alaska Native  Black/African American  Native Hawaiian or Other Pacific Islander  Asian  Caucasian  Othera | 10 (0.5)  332 (17.0)  3 (0.2)  59 (3.0)  1551 (79.3)  1 (<0.1) |
| Age, years  Mean  Minimum, maximum | 44.9  18, 75 |

MDD, major depressive disorder.

\*For studies included, see Table 2. N denotes number of patients in the safety set.

a Includes American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Other, and Unknown categories.